Application of glaucocalyxin A in preparation of anticoagulation medicaments

A kind of bluecalyxine, anticoagulant technology, which is applied in the application field of bluecalyxine in the preparation of anticoagulant drugs

Inactive Publication Date: 2012-08-22
CHINA PHARM UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether cerulein A has anticoagulant effect has not been reported, and the present invention finds that the drug has anticoagulant activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of glaucocalyxin A in preparation of anticoagulation medicaments
  • Application of glaucocalyxin A in preparation of anticoagulation medicaments
  • Application of glaucocalyxin A in preparation of anticoagulation medicaments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0010] 1 Materials and Instruments

[0011] 1.1 Drugs and reagents

[0012] Cylindrine A (mass fraction ≥ 98%, HPLC) provided by Suzhou Liyuan Pharmaceutical Technology Co., Ltd., prepared with 0.5% CMC-Na for animal administration, and DMSO was used to aid dissolution in vitro experiments. The final concentration of DMSO in the reaction system was 0.1%. Aspirin enteric-coated tablets (batch number: H32026500), Nanjing Baijingyu Pharmaceutical Co., Ltd., prepared with 0.5% CMC-Na for animal administration. Heparin (150U / mg, batch number: 091123), Nanjing Tusai Biotechnology Co., Ltd., prepared with distilled water. Prothrombin time (PT) kit (No.: YZB / Shanghai 0556-40-2009), activated partial thromboplastin time (APTT) kit (No.: YZB / Shanghai 0555-40-2009) and thrombin time (TT ) Kit (No.: YZB / Shanghai 0558-40-2009), Shanghai Sun Biological Products Co., Ltd.

[0013] 1.2 Animals

[0014] Rabbits, weighing 2.5kg, provided by Qinglongshan Animal Breeding Center, Jiangning Dis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to application of glaucocalyxin A and particularly relates to application of glaucocalyxin A in preparation of anticoagulation medicaments. The glaucocalyxin A can be used for remarkably prolonging the capillary coagulation time and tail tip bleeding time of mice, and remarkably prolonging the thrombin time (TT), prothrombin time (PT), activated partial thromboplastin time (APTT) and plasma recalcification time (PRT) of the mice. The glaucocalyxin A can be used for remarkably prolonging the TT, APTT and PRT for domestic rabbits in vitro. The results of in-vivo-administration anticoagulation experiments prove that the glaucocalyxin A can be used for remarkably prolonging the APTT and PRT of the mice, thereby prompting that the glaucocalyxin A can be used for inhibiting the generation of fibrin by disturbing intrinsic coagulation factor activity; and the remarkable prolonging of the TT proves the inhibition of transformation from fibrinogen to fibrin. The results of the in-vivo-administration anticoagulation experiments also prove that the glaucocalyxin A has a certain inhibition effect on extrinsic coagulation pathways since the glaucocalyxin A can be used for remarkably prolonging the PT. The results of in-vitro experiments prove that the glaucocalyxin A can be used for remarkably prolonging the APTT, PT and PRT, but has no obvious effects on the PT, thereby proving that the glaucocalyxin A realizes the anticoagulation effect in vitro mainly through inhibiting intrinsic coagulation pathways.

Description

technical field [0001] The present invention relates to the application of cyanine A, in particular to the application of cyanine A in the preparation of anticoagulant drugs. Background technique [0002] Thrombosis can occur in various parts of the circulatory system, such as veins, arteries, cardiac chambers and microcirculation, which are composed of fibrin and blood cells. In the process of thrombus formation, platelet activation and coagulation system activation play an important role. The two are closely related in the body. The thrombin produced after the coagulation system is activated is a powerful platelet activating factor, and the platelet activation will promote the coagulation process. Antithrombotic therapy mainly targets the coagulation system and platelets, which are called anticoagulant therapy and antiplatelet therapy, respectively. Currently, the most commonly used anticoagulant drugs include heparins and coumarins. The clinical value of these drugs has ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/122A61P7/02
Inventor 傅强马世平张陆勇王蕾李伟光王晓虎马占强
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap